Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay

Joseph Schappert, Frank H. Wians Jr., Eugene Schiff, David Smalley, Ronald Gambardella, William M. Lee, Jiaxi Wu, Philip Keiser, Dolores Peterson, Maria De Medina, Lawrence Baker, Barbara Preisel-Simmons

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: It is important that serological assays detect antibodies to human immunodeficiency virus (HIV) in all infected individuals, including those infected with less prevalent, more diverse subtypes. Methods: Performance of the ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay was tested on 1344 samples from HIV-positive subjects, 6061 samples from groups at low-risk for HIV infection, and 1042 samples from groups at high-risk for HIV-1 and HIV-2 infection. Results were compared with those of an FDA-approved predicate assay. Results: The ADVIA Centaur EHIV Assay showed good precision with a diagnostic specificity of 99.9% and diagnostic sensitivity of 100%. HIV seroconversion was detected earlier in 6 panels, at the same time in 13 panels and later in only 1 of the panels when compared to the predicate assay, thereby narrowing the window period between infection and antibody detection. Of clinical significance, a blood donor sample that was indeterminate by HIV-1 Western blot and non-reactive by the predicate assay was repeatedly reactive in the ADVIA Centaur Assay and confirmed as positive by HIV-2 immunoblot. Conclusions: The ADVIA Centaur EHIV Assay is useful as an aid in the diagnosis of individuals infected with HIV-1 and/or HIV-2.

Original languageEnglish (US)
Pages (from-to)158-166
Number of pages9
JournalClinica Chimica Acta
Volume372
Issue number1-2
DOIs
StatePublished - Oct 2006
Externally publishedYes

Fingerprint

Viruses
HIV-2
HIV-1
Assays
HIV
Virus Diseases
Antibodies
Blood Donors
Western Blotting
Infection
Blood

Keywords

  • ADVIA Centaur
  • AIDS
  • Bayer
  • Clinical trial
  • HIV
  • Human immunodeficiency virus

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry

Cite this

Schappert, J., H. Wians Jr., F., Schiff, E., Smalley, D., Gambardella, R., Lee, W. M., ... Preisel-Simmons, B. (2006). Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay. Clinica Chimica Acta, 372(1-2), 158-166. https://doi.org/10.1016/j.cca.2006.04.017

Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay. / Schappert, Joseph; H. Wians Jr., Frank; Schiff, Eugene; Smalley, David; Gambardella, Ronald; Lee, William M.; Wu, Jiaxi; Keiser, Philip; Peterson, Dolores; De Medina, Maria; Baker, Lawrence; Preisel-Simmons, Barbara.

In: Clinica Chimica Acta, Vol. 372, No. 1-2, 10.2006, p. 158-166.

Research output: Contribution to journalArticle

Schappert, J, H. Wians Jr., F, Schiff, E, Smalley, D, Gambardella, R, Lee, WM, Wu, J, Keiser, P, Peterson, D, De Medina, M, Baker, L & Preisel-Simmons, B 2006, 'Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay', Clinica Chimica Acta, vol. 372, no. 1-2, pp. 158-166. https://doi.org/10.1016/j.cca.2006.04.017
Schappert J, H. Wians Jr. F, Schiff E, Smalley D, Gambardella R, Lee WM et al. Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay. Clinica Chimica Acta. 2006 Oct;372(1-2):158-166. https://doi.org/10.1016/j.cca.2006.04.017
Schappert, Joseph ; H. Wians Jr., Frank ; Schiff, Eugene ; Smalley, David ; Gambardella, Ronald ; Lee, William M. ; Wu, Jiaxi ; Keiser, Philip ; Peterson, Dolores ; De Medina, Maria ; Baker, Lawrence ; Preisel-Simmons, Barbara. / Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay. In: Clinica Chimica Acta. 2006 ; Vol. 372, No. 1-2. pp. 158-166.
@article{82ce7886f1fe4b5093ff67e76e49a87c,
title = "Multicenter Evaluation of the Bayer ADVIA Centaur{\circledR} HIV 1/O/2 Enhanced (EHIV) Assay",
abstract = "Background: It is important that serological assays detect antibodies to human immunodeficiency virus (HIV) in all infected individuals, including those infected with less prevalent, more diverse subtypes. Methods: Performance of the ADVIA Centaur{\circledR} HIV 1/O/2 Enhanced (EHIV) Assay was tested on 1344 samples from HIV-positive subjects, 6061 samples from groups at low-risk for HIV infection, and 1042 samples from groups at high-risk for HIV-1 and HIV-2 infection. Results were compared with those of an FDA-approved predicate assay. Results: The ADVIA Centaur EHIV Assay showed good precision with a diagnostic specificity of 99.9{\%} and diagnostic sensitivity of 100{\%}. HIV seroconversion was detected earlier in 6 panels, at the same time in 13 panels and later in only 1 of the panels when compared to the predicate assay, thereby narrowing the window period between infection and antibody detection. Of clinical significance, a blood donor sample that was indeterminate by HIV-1 Western blot and non-reactive by the predicate assay was repeatedly reactive in the ADVIA Centaur Assay and confirmed as positive by HIV-2 immunoblot. Conclusions: The ADVIA Centaur EHIV Assay is useful as an aid in the diagnosis of individuals infected with HIV-1 and/or HIV-2.",
keywords = "ADVIA Centaur, AIDS, Bayer, Clinical trial, HIV, Human immunodeficiency virus",
author = "Joseph Schappert and {H. Wians Jr.}, Frank and Eugene Schiff and David Smalley and Ronald Gambardella and Lee, {William M.} and Jiaxi Wu and Philip Keiser and Dolores Peterson and {De Medina}, Maria and Lawrence Baker and Barbara Preisel-Simmons",
year = "2006",
month = "10",
doi = "10.1016/j.cca.2006.04.017",
language = "English (US)",
volume = "372",
pages = "158--166",
journal = "Clinica Chimica Acta",
issn = "0009-8981",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Multicenter Evaluation of the Bayer ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay

AU - Schappert, Joseph

AU - H. Wians Jr., Frank

AU - Schiff, Eugene

AU - Smalley, David

AU - Gambardella, Ronald

AU - Lee, William M.

AU - Wu, Jiaxi

AU - Keiser, Philip

AU - Peterson, Dolores

AU - De Medina, Maria

AU - Baker, Lawrence

AU - Preisel-Simmons, Barbara

PY - 2006/10

Y1 - 2006/10

N2 - Background: It is important that serological assays detect antibodies to human immunodeficiency virus (HIV) in all infected individuals, including those infected with less prevalent, more diverse subtypes. Methods: Performance of the ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay was tested on 1344 samples from HIV-positive subjects, 6061 samples from groups at low-risk for HIV infection, and 1042 samples from groups at high-risk for HIV-1 and HIV-2 infection. Results were compared with those of an FDA-approved predicate assay. Results: The ADVIA Centaur EHIV Assay showed good precision with a diagnostic specificity of 99.9% and diagnostic sensitivity of 100%. HIV seroconversion was detected earlier in 6 panels, at the same time in 13 panels and later in only 1 of the panels when compared to the predicate assay, thereby narrowing the window period between infection and antibody detection. Of clinical significance, a blood donor sample that was indeterminate by HIV-1 Western blot and non-reactive by the predicate assay was repeatedly reactive in the ADVIA Centaur Assay and confirmed as positive by HIV-2 immunoblot. Conclusions: The ADVIA Centaur EHIV Assay is useful as an aid in the diagnosis of individuals infected with HIV-1 and/or HIV-2.

AB - Background: It is important that serological assays detect antibodies to human immunodeficiency virus (HIV) in all infected individuals, including those infected with less prevalent, more diverse subtypes. Methods: Performance of the ADVIA Centaur® HIV 1/O/2 Enhanced (EHIV) Assay was tested on 1344 samples from HIV-positive subjects, 6061 samples from groups at low-risk for HIV infection, and 1042 samples from groups at high-risk for HIV-1 and HIV-2 infection. Results were compared with those of an FDA-approved predicate assay. Results: The ADVIA Centaur EHIV Assay showed good precision with a diagnostic specificity of 99.9% and diagnostic sensitivity of 100%. HIV seroconversion was detected earlier in 6 panels, at the same time in 13 panels and later in only 1 of the panels when compared to the predicate assay, thereby narrowing the window period between infection and antibody detection. Of clinical significance, a blood donor sample that was indeterminate by HIV-1 Western blot and non-reactive by the predicate assay was repeatedly reactive in the ADVIA Centaur Assay and confirmed as positive by HIV-2 immunoblot. Conclusions: The ADVIA Centaur EHIV Assay is useful as an aid in the diagnosis of individuals infected with HIV-1 and/or HIV-2.

KW - ADVIA Centaur

KW - AIDS

KW - Bayer

KW - Clinical trial

KW - HIV

KW - Human immunodeficiency virus

UR - http://www.scopus.com/inward/record.url?scp=33747839496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747839496&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2006.04.017

DO - 10.1016/j.cca.2006.04.017

M3 - Article

VL - 372

SP - 158

EP - 166

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -